GlassScriptPhysician profile
Lindsay Michelle Wood
NPI 1083143762
$1,026.94
in general payments reported to CMS, 2019-2025
12 companies · $661 in 2025
The $661 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $365 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.45 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $315.99 | 2024-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $206.44 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $148.12 | 2024-2025 | Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $90.92 | 2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $84.73 | 2024-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $49.26 | 2025 | Rexulti, Abilify Asimtufii |
| Janssen Scientific Affairs, LLC | $25.17 | 2024 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.41 | 2024 | Caplyta |
| Indivior INC. | $23.92 | 2024 | Sublocade |
| Alkermes, INC. | $23.04 | 2024 | Vivitrol |
| Braeburn INC. | $19.33 | 2024 | Brixadi |
| Supernus Pharmaceuticals, INC. | $15.61 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.